Enfuvirtide

Enfuvirtide (T20; DP178) is an anti-HIV-1 fusion inhibitor peptide.

Product Specifications

CAS Number

[159519-65-0]

Product Name Alternative

T20; DP178

UNSPSC

12352209

Hazard Statement

H315, H319, H335

Target

HIV

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Enfuvirtide.html

Purity

99.93

Solubility

DMSO : 6.67 mg/mL (ultrasonic; adjust pH to 8 with NH4OH) |H2O : < 0.1 mg/mL

Smiles

O=C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC=N2)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CC(N)=O)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](CC9=CC=CC=C9)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C

Molecular Formula

C204H301N51O64

Molecular Weight

4491.88

Precautions

H315, H319, H335

References & Citations

[1]Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep. 2017 Mar 30;7:45647.|[2]Cao P, et al. The improved efficacy of Sifuvirtide compared with Enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. PLoS One. 2017 Feb 16;12 (2) :e0171567.|[3]Wang X, et al. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol. 2017 Mar 6;8:210.